Main content

TransBioBC - Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction

 

Research Highlights:

Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.
"Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study"
Clinical Cancer Research. 2016 Mar 29.

 Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A.
"Developing proteomic biomarkers for bladder cancer: towards clinical application"
Nat Rev Urol. 2015 Jun;12(6):317-330

TRANSBIOBC_PAMPHLET_PUBLIC_V3 (PDF)

 

TransBioBC is an FP7- Health project funded by the EU Commission under Grant Agreement No.: 601933

Bladder cancer (BC) ranks second in incidence and mortality rates among cancers of the genitourinary tract, accounting annually for more than 350,000 new cases worldwide. Currently, clinical diagnosis and monitoring of bladder cancer (BC) relies on cystoscopy, an invasive and costly procedure. Additionally, due to high recurrence rates, BC management necessitates frequent patient follow-up, constituting BC one of the costliest types of cancer. Thus, there is a clear clinical need for the development of novel non-invasive and cost-effective approaches for the timely detection of BC recurrence and/or progression.

The TransBioBC project aims to identify novel biomarkers (BM) for BC recurrence and progression in urine using powerful state-of-the-art technological platforms. These platforms were developed through extensive foreground work undertaken within the contexts of the FP7 EU projects DECanBio and GENINCA by the TransBioBC Consortium Members. The objective of TransBioBC project is to translate this work in the field of BC. In particular, the project employs the technological platforms CE-MS and micro-ELISA in order to develop optimal non-invasive urine tests for monitoring BC recurrence and progression in routine clinical practice.

Our project uniquely integrates leading field experts, including clinical experts and internationally renown basic science researchers in proteome analysis and high throughput immunoassay development, in an implementation-oriented workflow. Strict monitoring of assay analytical performance conducted in well-characterized clinical samples are combined with in-depth knowledge of regulatory requirements, so as to best define added value of the project findings in clinical practice. Collectively, the TransBioBC project will provide strong evidence for the utility of the new BM directly in BC clinical management. Project findings are expected to be also informative for the development of novel BC drug targets and clinical trials.

TransBioBC is an FP7- Health project funded by the EU Comission under grant agreement no: 601933

  

             

FP7-logo

Contact Us